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Abstract: Objectives To determine the most recent prevalence, transmission patterns and risk factors of
transmitted drug-resistance mutations (TDRMs) in Cameroon, we initiated a multicentre study monitor-
ing HIV-1 drug resistance in newly HIV-1-diagnosed individuals using a novel next-generation sequencing
(NGS) assay applicable to fingerprick dried blood spot (DBS) samples. Methods Fingerprick DBS sam-
ples and questionnaires were collected from 360 newly HIV-1-diagnosed individuals in four hospitals in
urban areas in Cameroon in the years 2015-16. We developed an HIV-1 protease and reverse transcriptase
drug resistance genotyping assay applicable to DBS samples and HIV-1 genomes of groups M, N and O.
The WHO 2009 list of mutations for surveillance of transmitted drug-resistant HIV strains was used to
analyse TDRMs. Results Applying our ’DBS-NGS-genotypic resistance test’, baseline HIV-1 drug resis-
tance data were successfully obtained from 82.8% (298/360) of newly diagnosed individuals. At nucleotide
frequencies >15%, TDRMs to NRTIs were observed in 3.0% (9/298), to NNRTIs in 4.0% (12/298) and to
PIs in 1.3% (3/240). The NNRTI mutation K103N was most commonly detected (2.7%). Expanding the
analysis to low-abundance TDRMs, i.e. 3%-15%, 12 additional individuals (4.0%) harbouring TDRMs
were identified. Having unprotected sex with a known HIV-1-positive person was significantly associated
with the transmission of DRMs (adjusted OR 9.6; 95% CI 1.79-51.3). Conclusions The prevalence of
transmitted HIV-1 drug resistance is currently low in the study sites in Cameroon. Evidence of some
risky sexual behaviours depicts a public health problem with possible implications for the prevention of
new HIV-1 infections.
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Objectives: To determine the most recent prevalence, transmission patterns and risk factors of transmitted
drug-resistance mutations (TDRMs) in Cameroon, we initiated a multicentre study monitoring HIV-1 drug resist-
ance in newly HIV-1-diagnosed individuals using a novel next-generation sequencing (NGS) assay applicable to
fingerprick dried blood spot (DBS) samples.
Methods: Fingerprick DBS samples and questionnaires were collected from 360 newly HIV-1-diagnosed individ-
uals in four hospitals in urban areas in Cameroon in the years 2015–16. We developed an HIV-1 protease and re-
verse transcriptase drug resistance genotyping assay applicable to DBS samples and HIV-1 genomes of groups
M, N and O. The WHO 2009 list of mutations for surveillance of transmitted drug-resistant HIV strains was used
to analyse TDRMs.
Results: Applying our ‘DBS-NGS-genotypic resistance test’, baseline HIV-1 drug resistance data were success-
fully obtained from 82.8% (298/360) of newly diagnosed individuals. At nucleotide frequencies .15%, TDRMs to
NRTIs were observed in 3.0% (9/298), to NNRTIs in 4.0% (12/298) and to PIs in 1.3% (3/240). The NNRTImutation
K103N was most commonly detected (2.7%). Expanding the analysis to low-abundance TDRMs, i.e. 3%–15%,
12 additional individuals (4.0%) harbouring TDRMs were identified. Having unprotected sex with a known HIV-1-
positive personwas significantly associatedwith the transmission of DRMs (adjusted OR 9.6; 95% CI 1.79–51.3).
Conclusions: The prevalence of transmitted HIV-1 drug resistance is currently low in the study sites in
Cameroon. Evidence of some risky sexual behaviours depicts a public health problem with possible implications
for the prevention of newHIV-1 infections.
Introduction
Since its implementation, combination ART has greatly reduced
the morbidity and mortality caused by HIV-1 infections world-
wide.1 However, this improvement is being hampered by the
emergence of drug-resistant viruses,2 posing a more serious prob-
lem today in resource-limited settings compared with resource-
rich settings.3,4AcquiredHIV-1 drug resistance developswhen viral
mutations emerge due to viral replication in the presence of
insufficient levels of antiretroviral drugs; meanwhile, transmitted
HIV-1 drug resistance occurs when individuals are infected with a
drug-resistant virus.5 Also, minority drug-resistant HIV-1 variants,
undetected by conventional genotyping may impair the outcome
of ART.6–8 However, the impact of pre-existing minority drug-
resistant HIV-1 variants on first-line ART still remains unclear.9–12
Cameroon, like many other developing countries, is increasing
its HIV prevention and treatment efforts, which has led to the
widespread use of ART through national scale-up plans. In 2015,
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the Joint UN Programme on HIV and AIDS (UNAIDS) estimated the
adult HIV-1 prevalence in Cameroon to be 4.5%, with about
620000 people living with HIV-1.13 In May 2016, ART eligibility in
the country was modified to include all individuals diagnosed with
HIV-1 in over 145 treatment centres (HIV Approved Treatment
Centres andHIVManagement Units) nationwide. In 2013, a survey
conducted in 15 HIV-1 treatment centres in Cameroon evaluating
HIV-1 drug resistance early warning indicators (EWIs) revealed
that only 33.3% of centres reached the desirable performance for
‘on-time pill pick-up’ while just 14.4% reached the desirable per-
formance of ‘no pharmacy stock-outs’.14 With limited healthcare
infrastructure for care and monitoring, Cameroon may face
increasing rates of HIV-1 drug resistance in the near future.
Surveillance of transmitted and acquired HIV-1 drug resistance
is essential for the management of ART programmes.5 Recent sys-
tematic reviews of published literature between 2014 and 2017 on
pretreatment HIV-1 drug resistance in adults from low- and
middle-income countries, including Cameroon, found that NNRTI
resistance was higher in more recent studies across Eastern Africa,
Southern Africa, Western and Central Africa, Latin America
and Asia.4,15 In Cameroon, very few studies on HIV-1 drug resist-
ance in untreated patients have been conducted so far, and report
low to moderate prevalence rates (,8%) of transmitted drug
resistance mutations (TDRMs).16–18 These studies were performed
with few samples (median 141), targeting special groups of people,
such as pregnant women and blood donors, and/or conducted in
specific geographical areas, mainly the south-eastern part of the
country. Findings from these data are quite useful but a larger and
more diverse sample population would better estimate the preva-
lence of TDRMs in Cameroon. Another unique circumstance in
Cameroon is that all major groups and subtypes of HIV-1 co-circu-
late,19,20which represents a challenge for genotypic HIV-1 drug re-
sistance testing.
Here, we have developed a next-generation sequencing (NGS)
assay for genotypic HIV-1 drug resistance testing applicable to dried
blood spot (DBS) samples. Using DBS samples overcomes the chal-
lenges with handling plasma samples in resource-limited settings.
Using this test, we determined the recent prevalence of transmitted
HIV-1 drug resistance and its associated risk factors in newly diag-
nosed patients from thewestern andnorthern areas of Cameroon.
Materials and methods
Establishment of the genotypic HIV-1
drug resistance assay
The newly designed genotypic HIV-1 drug-resistance assay, DBS-NGS-
genotypic resistance test (DBS-NGS-GRT), encompasses amino acids 1–99
of the HIV-1 protease (PR) and 1–321 of the reverse transcriptase (RT). PR
and RT genes are amplified in two fragments, each fragment comprising a
semi-nested PCR of cDNA transcribed from RNA. The virus stock HIV-1NL4-3
subtype B, several primary virus isolates andHIV-1 subtypes A, C, D, G, F and
CRF02_AE were used to develop and validate the assay. Details regarding
the establishment and validation of our DBS-NGS-GRT assay are described
in File S1 (available as Supplementary data at JACOnline).
Study population and data collection
Between April 2015 and July 2016, fingerprick DBS samples were collected
from 360 patients in four different hospitals in Cameroon, representing
three regions of the country: the North-West (Bamenda Regional Hospital
and Ndop District Hospital), South-West (Kumba District Hospital) and
Adamawa (Ngaoundere Regional Hospital) regions (Figure 1a). Participants
had to meet the following inclusion criteria: (i) age 18years; (ii) newly
diagnosed with HIV-1; and (iii) with no previous exposure to any form of
ART. The procedure for fingerprickDBS collection andhandlingwas adapted
from theWHOmanual for HIV drug resistance testing using DBS samples.21
This manual was distributed to all four hospitals (File S2). A questionnaire
capturing patient demographics, clinical data and sexual behaviours was
also administered (File S3). The samples and completed questionnaires
from all sampling sites were sent at room temperature by express mail to
the Division of Infectious Diseases and Hospital Epidemiology of the
University Hospital of Zurich in Switzerland, where they were stored at
#80C until further procedures. Details on the handling and shipment of
fingerprick DBS samples can be found in File S1.
Ethics statement
This study was approved by the National Ethics Committee of Cameroon
(Number: 2015/01/539/CE/CNERSH/SP) and written informed consent was
obtained fromeach participant.
Laboratory methods and data analyses
HIV-1 RNA was isolated from an equivalent of 100lL of blood (two spots)
on aWhatmanV
R
903 protein saver card (DBS sample). DNase-treated HIV-1
RNA was reverse-transcribed and amplified by two semi-nested PCRs using
the primers shown in Table S1. PCR products were purified, quantified and
sequenced with the Illumina MiSeq system. Sequencing reads were
retrieved, processed andmutationswere called withMinVar (git.io/minvar),
a tool to discover and annotate mutations from NGS of HIV-1
populations.22Mutations were called with a cut-off of 3% and finally anno-
tated according to the Stanford HIV Drug Resistance Database,23 version
8.1.1 (https://hivdb.stanford.edu/). The assessment of TDRMs was done
using the WHO 2009 list of mutations for surveillance of transmitted drug-
resistant HIV strains24 (https://hivdb.stanford.edu/page/who-sdrm-list/).
Phylogenetic and statistical analyses were also performed on sequences
and questionnaire data. The above methods are described in detail in File
S1.
Results
Demographic and baseline characteristics of patients
In total, fingerprick DBS samples were collected from 360 newly
diagnosedpatients in four hospitals in Cameroon. Three of the hos-
pitals are located in urban areas (sites A, B and D) and one in a
semi-urban area (site C; Figure 1a). FromApril 2015 until July 2016,
51, 210, 35 and 64 patients were enrolled in the study by the
centres A, B, C and D, respectively. DBS samples were obtained
from each participant and completed questionnaires were re-
turned by 334 (92.8%) participants (Figure 1b). In the following
analysis, data from patients for whomHIV-1 RNAwas successfully
amplified and sequenced (n"298)were included, as well as ques-
tionnaire data frompatientswithHIV-1 sequences (n"289).
Demographic and clinical baseline data are shown in Table 1.
Themedian agewas 36years and themajority of patientswere fe-
male (63%). Patients were first diagnosed with HIV-1 infection at
all WHO clinical stages25with 38.1% at stage 2. Themedian CD4!
T cell count was 303 (range 1–1112) cells/mm3 of blood. The
median HIV-1 cDNA log10 copy number/mL of blood in DBS
samples, as estimated by quantitative PCR (qPCR) of HIV-1 RNA re-
covered from DBS samples, was 4.4 (range 3.7–5.9). No patients
Mbunkah et al.
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had viral load records because this is hardly done for pretreatment
patients due to limited resources inmost hospitals in Cameroon.
Establishment and validation of the amplification of
HIV-1 RNA from DBS samples
We first developed an amplification protocol applicable to DBS
samples for the establishment of a genotypic HIV-1 PR and RT
drug resistance assay. This assay is universal, i.e. applicable to all
heterogeneous HIV-1 subtypes i.e., applicable to HIV-1 genomes
of groups M, N and O. HIV-1 RNA was isolated from an equivalent
of 100lL of blood on aWhatmanV
R
903 protein saver card, reverse-
transcribed and amplified by two semi-nested PCRs. To determine
the applicability in terms of diverse HIV-1 subtypes and the sensi-
tivity, limited diluted HIV-1-spiked DBS samples (HIV-1 subtypes A,
B, C, D, G, F and CRF02_AE) were tested. All these HIV-1 subtypes
were successfully amplified with a lower limit of detection of 1000
HIV-1 RNA copies/mL (Table S2). The error rates generated by PCR
and NGS ranged from 0.04% to 0.66% andwere previously investi-
gated using the same reagents and kits that were used in this
study.26
We proceeded to apply our established DBS-NGS-GRT to the
360 patient fingerprick DBS samples. Amplification of HIV-1 PR
and/or RT was successful in 298/360 (82.8%) DBS samples
(Figure 1b). From 240/298 (80.5%) DBS samples, both amplicons
were generated, while from 58/298 (19.5%) DBS samples only the
RT region was successfully amplified. Investigating the possible
reason for amplification failure in 62 DBS samples, we first exam-
ined the correlation to the CD4! T cell countmeasured at the hos-
pitals in Cameroon, i.e. as a surrogate marker for disease
progression and viral load. A significantly lower CD4! T cell count
(P,0.0001) was observed for patients whose samples were suc-
cessfully amplified compared with those whose samples failed
amplification (Figure S1a). Secondly, we quantified and compared
the HIV-1 cDNA copy numbers in DBS samples in those two groups.
Successful amplification was significantly associated with higher
HIV-1 cDNA copy numbers (P,0.0001) (Figure S1b). The subtype
diversity in this study was quite high as all group M HIV-1 subtypes
and circulating recombinant forms previously known to exist in
Cameroon were detected in patients’ samples (Figure 2c). In sum-
mary, we developed and applied a highly efficient, universal HIV-1
PR and RT amplification procedure for DBS samples.
Prevalence of HIV-1 transmitted drug resistance
Sequence results were obtained from 298 successful amplicons
(Figure 1b). Overall, TDRMs were found in 31/298 patients (10.4%;
95% CI 7.2%–14.4%). In those individuals, theminimum coverage
per nucleotide was 439 (Table 2; patient 5) and the minimum
HIV-1 cDNA copy number sequencedwas 131 copies/5lL (Table 2;
patient 22) allowing a cut-off for low-abundance TDRMs at 3%.
TDRMs were checked for APOBEC3G/F signatures: no G-to-A hyper-
mutationswere detected in theNGS reads.
First, we investigated the prevalence of TDRMs at frequencies
.15%, i.e. which would also be detectable by population
sequencing commonly performed by Sanger sequencing. In
19/298 patients (6.4%; 95% CI 3.9%–9.8%), TDRMs were de-
tected at frequencies .15% (Figure 2a). Here, TDRMs to PIs were
detected in 3/240 patients (1.3%; 95% CI 0.3%–3.6%), to NRTIs







HIV-1 RNA successfully 
amplified & sequenced  
n=298  (82.8%) 
PR + RT:  n=240 
Only RT:  n=58 




Number of participants enrolled 
DBS: n=360 




n=62  (17.2%) 
Figure 1. Geographical distribution of participating hospitals and study outcome. (a) Map of Cameroona showing the participating hospitals: A,
District Hospital Kumba; B, Regional Hospital Bamenda; C, District Hospital Ndop; and D, Regional Hospital Ngaoundere. (b) Enrolled participants,
HIV-1 PR and RT amplification and return of completed questionnaires. aMap adapted from: https://www.google.ch/maps/place/Cameroon/.
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A 44 (15.2) 0 (0) 44 (17.1) 0.012*w
B 193 (66.8) 23 (74.2) 170 (65.9)
C 13 (4.5) 0 (0) 13 (5.0)
D 39 (13.5) 8 (25.8) 31 (12.0)
Age (years), median (range) 36 (18–68) 41 (18–60) 36 (18–68) 0.861†
Gender
male 107 (37.0) 9 (29.0) 98 (38.0) 0.329w
female 182 (63.0) 22 (71.0) 160 (62.0)
Occupation
skilled worker 90 (31.1) 8 (25.8) 82 (31.8) 0.594w
unskilled worker 152 (52.6) 19 (61.3) 133 (51.6)
applicant/student 47 (16.3) 4 (12.9) 43 (16.6)
Level of education
none 9 (3.1) 0 (0) 9 (3.5) 0.843d
primary 135 (46.7) 14 (45.2) 121 (46.9)
secondary 108 (37.4) 14 (45.2) 94 (36.4)
university 34 (11.8) 3 (9.7) 31 (12.0)
other 3 (1.0) 0 (0) 3 (1.2)
Marital status
single 104 (36.0) 7 (22.6) 97 (37.6) 0.110w
married 121 (41.9) 12 (38.7) 109 (42.2)
divorced 17 (5.9) 4 (12.9) 13 (5.1)
widow(er) 40 (13.8) 6 (19.4) 34 (13.2)
cohabiting 7 (2.4) 2 (6.5) 5 (1.9)
WHO clinical staging
primary infection 55 (19.0) 7 (22.6) 48 (18.6) 0.866w
stage 1 70 (24.2) 7 (22.6) 63 (24.4)
stage 2 110 (38.1) 13 (41.9) 97 (37.6)
stage 3 50 (17.3) 4 (12.9) 46 (17.8)
stage 4 4 (1.4) 0 (0) 4 (1.6)
CD4! T cell count (cells/mm3 blood), median (range) 303 (1–1112) 301 (13–940) 296 (1–1112) 0.569k
HIV-1 cDNA copy number in DBS sample (copies/mL),
median (range)
25119 (5012–794328) 63096 (5012–501187) 25119 (5012–794328) 0.0006*k
0.2713pk
Sexual orientation
MSM 4 (1.4) 0 (0) 4 (1.6) 0.634d
heterosexual 285 (98.6) 31 (100) 254 (98.4)
HIV-1 status of stable partner
positive 37 (12.8) 5 (16.1) 32 (12.4) 0.709w
negative 32 (11.1) 2 (6.5) 30 (11.6)
I don’t know 207 (71.6) 24 (77.4) 183 (71)
no partner 13 (4.5) 0 (0.0) 13 (5.0)
Condom use before diagnosis
never 86 (29.8) 7 (22.6) 79 (30.6) 0.478d
sometimes 185 (64.0) 21 (67.7) 164 (63.6)
always 18 (6.2) 3 (9.7) 15 (5.8)
No. of sexual encounters with an occasional
partner1 year before diagnosis
none 77 (26.6) 7 (22.6) 70 (27.1) 0.923w
one 75 (26.0) 9 (29.0) 66 (25.6)
two 49 (17.0) 6 (19.4) 43 (16.7)




12/298 patients (4.0%; 95% CI 2.1%–6.9%). Five patients (1.7%;
5/298; 95% CI 0.5%–3.9%) had TDRMs to both NRTIs and NNRTIs,
while no individual harboured mutations to both PR and RT drug
classes. Expanding the analysis to low-abundance TDRMs,
i.e. 3%–15%, 12/298 additional individuals (4.0%; 95% CI
2.1%–6.9%) were identified. As observed for high-abundance
TDRMs, the majority of low-abundance TDRMs were associated
with resistance to NNRTIs (Figure 2b).
Details of the different characteristics, mutation types and their
percentage abundance for the 31 individuals with low- and high-
abundance TDRMs are shown in Table 2. The most commonly de-
tected TDRM was the K103Nmutation: 8/298 patients (2.7%; 95%
CI 1.2%–5.2%), in seven of those patients occurring as a high-
abundance TDRM (Table 2). The M184V mutation was detected in
4/298 patients (1.3%; 95% CI 0.4%–3.4%) at high frequencies and
the M184I mutation also in 4/298 patients (1.3%; 95% CI
0.4%–3.4%) at high (n"3) and low (n"1) frequencies. One pa-
tient harboured both theM184V andM184Imutations (Table 2).
The impact of TDRMs on future therapy response in patientswas
assessed with the scoring system of the Stanford HIV Drug
Resistance Database. In 51.6% (16/31; 95% CI 33.1%–69.8%)
cases, only low-level or potential low-level resistancewas observed.
Somepatients had a combination of twoor three resistance profiles
(low, intermediate or high) for different drugs (Table 2).
Transmission clusters of DRMs were not found within
and between study sites
To investigate any transmission clusters of drug resistance in the
study population, phylogenetic analysis was performed. From the
phylogenetic tree generated with our sequences, together with
the background sequences (Figure 3a and File S4), cluster analysis
revealed 200 clusters in total (bootstrap values .90%). Twenty-
five of these clusters included individuals from our study
population. Seventeen of those clusters included more than one
individual of our study population. Of these, two clusters had pa-
tients with a DRM. One cluster with two study patients was found
with both of them having a drug resistance mutation (E138G)
(Figure 3b). Another cluster had two study patients with one of
themhaving a DRM (M46I) (Figure 3c).
Comparison of demographic, clinical and risky
sexual parameters between individuals with and
without TDRMs
Besides acquiring patients’ clinical and demographic data, the
questionnaire also sought to examine the sexual attitudes of pa-
tients for any risky behaviours before HIV-1 diagnosis. This analysis
could only be performed for the 289 patients with returned ques-
tionnaires and NGS data, out of the 298 patients with successfully
amplified and sequenced samples, leaving out 9 patients withNGS
data but no questionnaires (Table 1). Therewas a significant differ-
ence in the number of patients with and without TDRMs between
the study sites, with site B having the highest frequency of patients
with TDRMs. We found a statistically significant difference (Mann–
Whitney U-test P"0.0006) between the cDNA copy numbers for
both groups (with and without TDRMs) but this difference became
not significant once we excluded data from patients with low-
abundance TDRMs. In a univariable logistic regression, it was found
that having unprotected sex with a known HIV-1-positive person
was significantly associated with the transmission of DRMs [OR 9.1









no 265 (91.7) 28 (90.3) 237 (91.9) 0.731d
yes 24 (8.3) 3 (9.7) 21 (8.1)
Ever paid for sex
no 269 (93.1) 30 (96.8) 239 (92.6) 0.495d
yes 20 (6.9) 1 (3.2) 19 (7.4)
Ever received money for sex
no 272 (94.1) 31 (100.0) 241 (93.4) 0.232d
yes 17 (5.9) 0 (0.0) 17 (6.6)
Unprotected sex with someone known to be HIV-1-positive
no 283 (97.9) 28 (90.3) 255 (98.8) 0.018*d
yes 6 (2.1) 3 (9.7) 3 (1.2)
Data are presented as n (%), unless otherwise stated.
*Statistically significant P values are shown in bold.
pExcluding data from patients with low-abundance TDRMs.
dP value obtained with the Fisher’s exact test.
wP value obtained with the v2 test.
kP value obtained with the Mann–Whitney U-test.
†P value obtained with the t-test.
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regression adjusted for age and sex, this was still significant
[OR 9.6 (95% CI 1.79–51.3, P"0.008)].
Discussion
Wehave developed a sensitive, specific and universal assay for the
determination of HIV-1 drug resistance using DBS samples and
applying NGS, suitable for up to 96 samples per MiSeq flow cell.
DBS samples serve as an attractive sampling alternative to plasma
especially in developing countries (resource-limited), overcoming
the challenges that come with handling plasma, such as success-
fullymaintaining the cold chain at#80C.
Our DBS-NGS-GRT was designed taking into account the very
high HIV-1 subtype distribution in Central Africa. The primers were
carefully designed to cover all major HIV-1 group M subtypes and
circulating recombinant forms (CRFs) as well. The overlapping
amplicon strategy used in the PCRs improved the sensitivity limit
for the DBS samples as it has been previously suggested that RNA
extracted from DBS samples can sometimes be fragmented or
broken27,28 (data not shown). These fingerprick DBS samples were
stored at various temperatures during collection, temporary stor-
age until shipment, transportation and storage until processing.
Some loss of HIV-1 RNA was even observed in all spiked DBS sam-
ples (Table S2), which were prepared and immediately stored
at#80C after desiccation. This is a common phenomenon with
DBS samples in general; furthermore, the degree of HIV-1 RNA loss
can also vary depending on the viral RNA extraction technique
used, someofwhich are not suitable for DBS samples.21,29
When patients’ fingerprick DBS samples were used, an 82.8%
amplification success rate was obtained. We found that the re-
maining 17.2% of patients whose samples failed to amplify prob-
ably had a low viral load at the time of sampling. Previously, it has
been suggested that DBS samples may be limited for the analysis
of viral RNA if the viral load is too low, i.e. less than 1000 HIV-1 RNA
copies/mL of plasma.29–31 Using spiked DBS samples, we also
reached a lower limit of detection at 1000 HIV-1 RNA copies/mL.
The lower limit of detection for our patients’ DBS samples seemed
higher, i.e. 5000 HIV-1 cDNA copies/mL of blood on DBSs.
However, these data might be difficult to compare since different
assays for the quantification were used and we cannot fully ex-
clude some primer mismatches in some of the failing-to-be-
amplified samples. Another possible reason for the drop in assay
sensitivity seen with patients’ fingerprick DBS samples compared
with spiked DBS samples is that the spiked DBS samples used for
assay developmentwent throughmore ideal conditions of prepar-
ation and storage.
So far, studies on transmitted HIV-1 drug resistance in
Cameroon are scarce and have focused on certain parts of the
country.16–18 For our study sites, no or only very few surveillance
data on HIV-1 TDRMs are available and they were obtained more
than a decade ago.32 Our study provides a comprehensive and
contemporary description of the prevalence of transmitted HIV-1
drug resistance among newly diagnosed HIV-1 patients in the
western and northern parts of Cameroon. By WHO classification,
the prevalence is low (,5%) for all three drug classes separately.33
4/240
3/240
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0.7
Figure 2. TDRMs detected at high (.15%) (a) and low (3%–15%) (b) frequencies in 298 newly HIV-1-diagnosed patients in Cameroon from April
2015 to July 2016 and HIV-1 subtype distribution (c). URFs, unique recombinant forms. This figure appears in colour in the online version of JAC and in
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The overall prevalence we report here is slightly lower than what
was reported for the eastern part of the country in 2011.17 Those
authors reported an overall prevalence of 7.8% with many more
TDRMs to NRTIs (5.3%) than NNRTIs (1.9%) and PIs (1.9%).
According to theWHO HIV drug resistance report for 2017,4,15 lev-
els of any pretreatment HIV drug resistance (PDR) was below 10%
in Cameroon. This same report with 321 individuals sampled in
2015 fromdifferent hospitals in Cameroondemonstrated compar-
able findings to ours for their 223 ART-naive individuals, with
similar prevalence rates and overlapping confidence intervals for
drug resistance to PIs, NRTIs, NNRTIs or any drug class. Our study
also saw unequal numbers of participants randomly enrolled from
each study site. The hospital in site B is the largest compared with
the others and enrolled the highest number of participants in the
study. ART was also introduced earlier to this population relative
to the other sites. The NNRTI mutation K103N and NRTImutations
M184V/I were most commonly detected in our study popula-

































Figure 3. Phylogenetic analysis of 298 patient sequences and 2359 background sequences from Cameroon downloaded from the Los Alamos HIV
database (http://www.hiv.lanl.gov). The furthest branches are HIV-1 groups O and N background sequences. (a) Phylogenetic tree with coloured tips:
grey tips, background sequences; brown tips, site A; red tips, site B; yellow tips, site C; and blue tips, site D. For a high-resolution electronic file of the
tree please see File S4. (b) Cluster with two study patients, both of them having a non-TDRM. (c) Cluster with two study patients, one of them having
a TDRM. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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nevirapine and lamivudine/emtricitabine,34 commonly prescribed
drugs in Cameroon. It is common to detect these DRMs among
patients treated with these drugs and experiencing virological fail-
ure,34 and they can subsequently transmit them.
We are also reporting one of the first studies on minority drug-
resistant HIV-1 variants in ART-naive patients in Cameroon. The
fact that the significant difference in the cDNA copy numbers be-
tween patients with and without TDRMs became not significant
once data from patients with low-abundance TDRMs were
excluded is an indication that this latter group of patients were
possibly infected for longer periods than the other individuals. Four
percent of the patients harboured TDRMs at frequencies between
3% and 15% and mostly against NNRTIs. This is lower than was
previously reported in ART-naive patients in Cameroon (17%–
20%)11 at frequencies .1%. Applying our range of 3%–15% to
their study population, the prevalence of low-abundance TDRMs
would decrease to 1.5%. Another study with NGS data from
32 ART-naive patients with highly diverse subtypes in Cameroon
found two minority variants constituting 7% (T215F/Y) and 18%
(K103N) of the quasispecies.35 Although the impact of these mi-
nority variants on the success of ART is not clearly known,36 a sub-
stantial number of our ART-naive patients harbour them. Thismay
give rise to the rapid selection of drug-resistant viruses, which can
subsequently lead to early therapy failure in treatment-naive pa-
tients receiving ART regimens with a low genetic resistance
barrier.6
It has been shown that phylogenetic analysis is a useful tool in
identifying clusters of HIV transmission since very related viral se-
quences may correlate with common social or risk-behaviour pat-
terns in individuals.37,38 Although we found no transmitted HIV-1
drug-resistant strains spreading in our study population, a large
Swiss survey on transmitted HIV-1 drug resistance conducted be-
tween 1996 and 2009 showed that DRMs are frequently transmit-
ted among ART-naive MSM.39 However, our sampling density is
probably considerably lower comparedwith the Swiss settings.
We observed that having unprotected sex with a known HIV-1-
positive person was significantly associated with the transmission
of DRMs. These patients had 9.6-fold higher odds of harbouring
genotypic drug-resistant HIV-1 strains, suggesting a more
advanced disease stage and possible ART experience of the DRM
transmitters. One factor we did not evaluate in this study is the pa-
tients’ history of sexually transmitted diseases. This has been
shown in Southern Taiwan to predispose patients to 7.8-fold
increased odds of becoming infected with genotypic drug-resist-
ant HIV-1 strains.40
In conclusion, we have established an assay for HIV-1 drug
resistance genotyping based on NGS, applicable to DBS samples
and genotyping all heterogeneous HIV-1 subtypes of at least
group M with similar sensitivity and specificity to other known DBS
assays.41–43 The sample type used, the assay’s sensitivity and
broad subtype coverage make it ideal for HIV-1 drug resistance
genotyping in areas with limited resources and a high HIV-1 sub-
type diversity. Although transmitted HIV-1 drug resistance is cur-
rently low in the study sites in Cameroon, continued surveillance is
still necessary to detect any changes in drug resistance trends
early enough. The evidence of some risky sexual behaviours found
in this study depicts a public health problemwith possible implica-
tions for the prevention of newHIV-1 infections in the country. This
information is important for future preventive intervention strat-
egies in the study sites and thewhole country at large.
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Thérapeutique Hospitalière En Réseau) (ESTHER 2017 project to H. A. M.
and K. J. M.) funded contributions to this project.
Transparency declarations
H. F. G. has been an adviser and/or consultant for Gilead and Merck and
has received unrestricted research and educational grants from Roche,
Gilead and Merck Sharp & Dohme. K. J. M. has received travel grants and
honoraria from Gilead Sciences, Roche Diagnostics, Tibotec, Bristol-Myers
Squibb and Abbott; the University of Zurich has received research grants
from Gilead, Roche and Merck Sharp & Dohme for studies that K. J. M.
serves as principal investigator and advisory board honoraria from Gilead
Sciences. All other authors: none to declare.
Author contributions
H. A. M. designed the study, developed the assay, researched and ana-
lysed data, and wrote the manuscript. A. M. designed the study ques-
tionnaire and analysed data. S. S., Y. L. K. and M. S. contributed to the
assay development. O. Z. analysed sequencing data. N. N. N., E. T. M., L.
M. B., B. A. S. and E. O. enrolled study participants and/or collected DBS
samples and questionnaires. R. D. K. co-designed the study questionnaire
and edited the manuscript. H. F. G. contributed towards supervision and
editing of the manuscript and leads the Zurich Primary HIV infection
study. K. J. M. designed the study, supervised the work and edited the
manuscript.
Supplementary data
Files S1 to S4, Tables S1 and S2 and Figure S1 are available as
Supplementary data at JAC Online.
References
1 Sterne JA, Hernán MA, Ledergerber B et al. Long-term effectiveness of po-
tent antiretroviral therapy in preventing AIDS anddeath: a prospective cohort
study. Lancet2005;366: 378–84.
2 Clutter DS, JordanMR, Bertagnolio S et al. HIV-1 drug resistance and resist-
ance testing. Infect Genet Evol2016;46: 292–307.
Low transmitted HIV-1 drug resistance in Cameroon JAC
1927
3 Scherrer AU, vonWyl V, YangWL et al. Emergence of acquired HIV-1 drug
resistance almost stopped in Switzerland: a 15-year prospective cohort ana-
lysis.Clin Infect Dis2016;62: 1310–7.
4 Gupta RK, Gregson J, Parkin N et al. HIV-1 drug resistance before initiation
or re-initiation of first-line antiretroviral therapy in low-income and middle-
income countries: a systematic review andmeta-regression analysis. Lancet
Infect Dis2018;18: 346–55.
5 WHO HIV Drug Resistance Report 2012. http://apps.who.int/iris/bitstream/
10665/75183/1/9789241503938_eng.pdf.
6 Metzner KJ, Giulieri SG, Knoepfel SA et al. Minority quasispecies of drug-
resistant HIV-1 that lead to early therapy failure in treatment-naive and -ad-
herent patients. Clin Infect Dis2009;48: 239–47.
7 Li JZ, Paredes R, Ribaudo HJ et al. Low-frequency HIV-1 drug resistance
mutations and risk of NNRTI-based antiretroviral treatment failure: a system-
atic reviewandpooled analysis. JAMA2011;305: 1327–35.
8 Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F et al. Low-frequency
drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based
ART: amulticohort European case-control study using centralized ultrasensi-
tive 454pyrosequencing. J Antimicrob Chemother2015;70: 930–40.
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